Drug profile · INN
griseofulvin, ultramicrocrystalline
GRISACTIN ULTRA
griseofulvin, ultramicrocrystalline (GRISACTIN ULTRA) is a tubulin inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — griseofulvin, ultramicrocrystalline
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 5
- Data quality
- 0.84
Quick answer
griseofulvin, ultramicrocrystalline (GRISACTIN ULTRA) is a tubulin inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tubulin inhibitor
Primary target: Tubulin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is griseofulvin, ultramicrocrystalline?
griseofulvin, ultramicrocrystalline (GRISACTIN ULTRA) is a tubulin inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for griseofulvin, ultramicrocrystalline?
GRISACTIN ULTRA is a marketed brand name for griseofulvin, ultramicrocrystalline. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of griseofulvin, ultramicrocrystalline?
griseofulvin, ultramicrocrystalline has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.